Martin, S., Pflumio, C., Trensz, P., Schaff-Wendling, F., Weindling, M. K., Fischbach, C., . . . Petit, T. (2023). Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak. Clinical breast cancer, 23(1), 32-37. https://doi.org/10.1016/j.clbc.2022.10.006
Citace podle Chicago (17th ed.)Martin, Sophie, et al. "Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak." Clinical Breast Cancer 23, no. 1 (2023): 32-37. https://doi.org/10.1016/j.clbc.2022.10.006.
Citace podle MLA (9th ed.)Martin, Sophie, et al. "Consequences of Discontinuing a 4/6 Cyclin D-Dependent Kinase Inhibitor During Endocrine Treatment in Hormone-Sensitive Metastatic Breast Cancer Patients in the Context of the COVID-19 Outbreak." Clinical Breast Cancer, vol. 23, no. 1, 2023, pp. 32-37, https://doi.org/10.1016/j.clbc.2022.10.006.